Literature DB >> 34350097

Extra nodal Rosai Dorfman disease masquerading as metastatic soft tissue sarcoma- A case report.

Sanjay Bhalchandra Londhe1, Kshitij Chandrakant Joshi2, Puja Iyengar Ambrish3.   

Abstract

Rosai Dorfman disease is rare benign disease of phagocytic histiocytosis usually present as painless massive lymphadenopathy. Extra nodal presentation of Rosai Dorfman disease is rare but also described. We hereby describe an unusual presentation of the extra nodal Rosai Dorfman disease with rapidly growing soft tissue lesion in the left thigh with associated osseous lesions in the right distal femur, left distal femur, left proximal tibia and presence of solitary pulmonary nodule. This case is unique as clinical presentation highly suspicious of soft tissue sarcoma but excision biopsy of thigh lesion showed Rosai Dorfman disease.Though RDD in extremities has been described in limited number of cases, to the best of our knowledge this is first case of lower extremity RDD associated with osseous lesions and pulmonary nodule but without lymphadenopathy.
© 2021 Delhi Orthopedic Association. All rights reserved.

Entities:  

Keywords:  Differential diagnosis; Metastasis; Rosai-dorfman disease; Soft tissue sarcoma

Year:  2021        PMID: 34350097      PMCID: PMC8319515          DOI: 10.1016/j.jcot.2021.101500

Source DB:  PubMed          Journal:  J Clin Orthop Trauma        ISSN: 0976-5662


  10 in total

Review 1.  Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity.

Authors:  E Foucar; J Rosai; R Dorfman
Journal:  Semin Diagn Pathol       Date:  1990-02       Impact factor: 3.464

Review 2.  Rosai-Dorfman disease: tumor biology, clinical features, pathology, and treatment.

Authors:  Samir Dalia; Elizabeth Sagatys; Lubomir Sokol; Timothy Kubal
Journal:  Cancer Control       Date:  2014-10       Impact factor: 3.302

3.  Sinus histiocytosis with massive lymphadenopathy. A newly recognized benign clinicopathological entity.

Authors:  J Rosai; R F Dorfman
Journal:  Arch Pathol       Date:  1969-01

4.  ["Catastrophic systemic lupus erythematosus" with Rosai-Dorfman sinus histiocytosis. Successful treatment with anti-CD20/rutuximab].

Authors:  F Petschner; U A Walker; A Schmitt-Gräff; M Uhl; H H Peter
Journal:  Dtsch Med Wochenschr       Date:  2001-09-14       Impact factor: 0.628

5.  Cutaneous rosai-dorfman disease: a clinical and histopathologic study of 25 cases in China.

Authors:  Yun-Yi Kong; Jin-Cheng Kong; Da-Ren Shi; Hong-Fen Lu; Xiong-Zeng Zhu; Jian Wang; Zhong-Wei Chen
Journal:  Am J Surg Pathol       Date:  2007-03       Impact factor: 6.394

6.  Rosai-Dorfman disease presenting as laryngeal masses.

Authors:  Serdar Ensari; Adin Selçuk; Hüseyin Dere; Noelia Perez; Serpil Dizbay-Sak
Journal:  Kulak Burun Bogaz Ihtis Derg       Date:  2008 Mar-Apr

7.  Five cases of cutaneous Rosai-Dorfman disease.

Authors:  H V Pitamber; W Grayson
Journal:  Clin Exp Dermatol       Date:  2003-01       Impact factor: 3.470

8.  Cathepsin D and E co-expression in sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease) and Langerhans' cell histiocytosis: further evidences of a phenotypic overlap between these histiocytic disorders.

Authors:  M Paulli; A C Feller; E Boveri; S Kindl; E Berti; R Rosso; H Merz; F Facchetti; C Gambini; F Bonetti
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

9.  Laryngeal Rosai-Dorfman Disease (Sinus Histiocytosis with Massive Lymphadenopathy): A Retrospective Study of 5 Cases.

Authors:  Yanyan Niu; Yongjin Li; Jian Wang; Xiaofeng Jin; Dahai Yang; Hong Huo; Wuyi Li
Journal:  Biomed Res Int       Date:  2017-07-09       Impact factor: 3.411

10.  Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease.

Authors:  Gaurav Goyal; Aishwarya Ravindran; Jason R Young; Mithun V Shah; N Nora Bennani; Mrinal M Patnaik; Grzegorz S Nowakowski; Gita Thanarajasingam; Thomas M Habermann; Robert Vassallo; Taimur Sher; Sameer A Parikh; Karen L Rech; Ronald S Go
Journal:  Haematologica       Date:  2020-01-31       Impact factor: 9.941

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.